Mayo Clinic Jacksonville (A Nonprofit Corporation)

Mayo Clinic Jacksonville (A Nonprofit Corporation), doing business as Scott Lynch MD, is a nonprofit clinical and research institution providing biomedical research, translational medicine, and healthcare services to federal agencies as a prime recipient on federal research grants and as a subcontractor on contract and grant work. The organization is a child entity of the larger Mayo Clinic system and operates from Jacksonville, Florida, with direct involvement in clinical research infrastructure and neurodegenerative disease investigation funded by the National Institutes of Health and the Defense Health Agency.

Mayo Clinic Jacksonville's federal footprint is dominated by research grants, not contracts. The vendor has received 495 total awards (69% prime, 31% sub) worth a combined $3.8 million in potential value, though obligated federal dollars total $1.16 billion—reflecting the distinction that SCI-reported service-contract data captures only a slice of the organization's actual federal work. The award data shows 30 awards in 2022, 44 in 2023, 73 in 2024, 52 in 2025, and 38 in 2026, indicating sustained research activity with a spike in 2024. Fifty-eight awards face ultimate completion within the next twenty-four months, carrying a combined potential value of $1.4 million and representing a recompete window across multiple NIH programs.

Federal customer concentration is steep and research-focused. The National Institute on Aging (NIA) leads by award count with 150 awards, followed by the broader NIH (73 awards), the National Cancer Institute (67 awards), the National Institute of Neurological Disorders and Stroke (61 awards), and the Defense Health Agency (26 awards)—together accounting for 76% of recent awards. NASA's Shared Services Center appears in top potential-value rankings with $1.4 million across four awards for space-based hematopoietic stem cell research. Mayo Clinic Jacksonville operates primarily as a research recipient, not a contract prime; the organization sits on two NASA IDIQs (75N92019D00031 with four task orders, 80JSC019D0026 with three) and holds GSA Schedule positions, but the bulk of federal engagement flows through grant mechanisms rather than contract vehicles.

Research capability centers on neurodegenerative disease investigation, cancer immunotherapy, cardiovascular disease mechanisms, and translational biomedical science. Recent prime grant work includes $2.277 million from NINDS (September 2026) for development of the PAIN (Pain AI Intervention) platform, a wearable sensor-based AI system for continuous pain monitoring and personalized opioid management; $1.878 million from NINDS for interrogating alpha-synuclein aggregate-associated proteomes in Lewy body disease; $1.879 million from NINDS for long-read sequencing to resolve genomic architecture of dementia; $683 thousand from the Defense Health Agency for targeting the Polycomb Repressive Complex 2 in neurofibromatosis type 2 and schwannomatosis; and $2.97 million from NIDDK for investigating the novel role of urinary urate in renal cystogenesis and water regulation in autosomal dominant polycystic kidney disease. Across this portfolio, Mayo Clinic Jacksonville demonstrates deep expertise in neurodegenerative diseases (Alzheimer's disease, Lewy body dementia, frontotemporal dementia, ALS), cancer biology (CAR-T cell engineering, immunotherapy resistance, glioblastoma therapeutics), and precision medicine through multimodal biomarker discovery.

The organization operates as a clinical research site and scientific collaborator across multiple NIH-led consortia and network trials, including the Dominantly Inherited Alzheimer Network (DIAN), the North American Prodromal Synucleinopathy Consortium for REM Sleep Behavior Disorder (NAPS2), the Framingham Heart Study, the Alzheimer's Clinical Trials Consortium (ACTC), and the StrokeNet satellite network. In this role, Mayo Clinic Jacksonville recruits participants, collects clinical and biofluid samples, performs neuropathological analysis, and maintains biorepositories (notably one of the world's largest collections of neurodegenerative tauopathies, particularly progressive supranuclear palsy). The organization also serves as a neuropathological hub for large consortia, providing post-mortem tissue procurement, processing, analysis, and reporting to multi-site research projects. These roles position Mayo Clinic Jacksonville as both a research-performing site with independent scientific investigators and as a federated clinical infrastructure asset supporting national research networks.

Sub-award footprint reflects Mayo Clinic Jacksonville's participation in larger research consortia anchored by academic medical centers and universities. Named prime grantees include Stanford University (INVESST pneumonia trial, FTD splicing biomarker validation), the University of Pennsylvania (spatial transcriptomics in dementia, cephalosporin allergy testing), Washington University (NAPS2, DIAN), Indiana University (early-onset Alzheimer's disease longitudinal study, ontology development), Yale University (vaccine safety knowledge graph), and the University of Colorado (double-stranded RNA and neurodegenerative disease pathology). The organization also acts as a clinical trial site under prime awardees such as the Trustees of Boston University (Framingham Heart Study), Northwestern University (atrial fibrillation monitoring trial), and others. In most cases, Mayo Clinic Jacksonville's sub role involves site operations, participant recruitment, clinical assessment, tissue banking, and neuropathological characterization—roles leveraging its clinical infrastructure and brain bank rather than delivery of new intellectual property or product development.

Mayo Clinic Jacksonville's federal grant profile has grown substantially year over year. In FY2022, the organization reported minimal SCI-captured service-contract activity (0.1 FTEs across 1 sub record). By FY2024 and FY2025, SCI records show 1.0 FTE across 2–3 sub records—a modest footprint that reflects the organization's primary reliance on direct NIH grants rather than federal service contracts. The distinction is material: while total obligated federal dollars to Mayo Clinic Jacksonville exceed $1.16 billion, SCI-reported federal service revenue (covering only contracts above $150,000) is negligible. The bulk of funding flows through NIH research project grants (R01, R35, U19, UG3/UH3), training and mentorship awards (K awards, R50 Research Specialist awards), and cooperative agreements—instruments that fall outside SCI's contract-focused reporting scope.

No SBA set-aside designations or HUBZone certifications appear in the source material. Mayo Clinic Jacksonville operates as a full-and-open prime on federal grants and as an uncompeted sub on large NIH-led consortia. The organization does not compete for GSA Schedule delivery orders or task-order-based procurements; its federal business model is receipt of peer-reviewed research grants from NIH institutes, the Defense Health Agency, NASA, and other science-funding agencies. Corporate structure identifies Mayo Clinic Jacksonville as a child of Mayo Clinic, a larger nonprofit health system. The organization's federal footprint and activity trajectory position it as a high-capacity neuroscience and translational research performer within the NIH ecosystem, not as a federal contractor or service provider in the traditional sense.